{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T01:41:56Z","timestamp":1777513316759,"version":"3.51.4"},"reference-count":13,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2007,11,1]],"date-time":"2007-11-01T00:00:00Z","timestamp":1193875200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Cutan Med Surg"],"published-print":{"date-parts":[[2007,11]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Alefacept blocks T-cell activation and induces apoptosis of memory T cells. It improves psoriasis vulgaris and may induce prolonged remissions. Experience with alefacept in palmar plantar pustulosis (PPP) is limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>The objective of the study was to observe the effectiveness and safety of alefacept in the treatment of PPP.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Alefacept was administered weekly for 16 weeks by intramuscular (IM) injection of 15 mg to 15 patients with moderate to very severe PPP. Patients were followed for an additional 12 weeks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Four weeks after 16 weeks of treatment, there was a 49.6% reduction in the Palmoplantar Pustulosis Psoriasis Area and Severity Index (PPPASI) and a 38.6% and a 64.5% reduction in total and fresh pustules, respectively. Eight weeks after dosing, 53.3% achieved PPPASI 50, 26.7% achieved PPPASI 75, and one patient was clear. The mean percent reduction in total pustules and fresh pustules was 46.1% and 61.2%, respectively; 73% had no pain, 53% had no itching, and 80% had no functional impairment. The palms responded better than the soles.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>This pilot showed that 16 weeks of once-weekly alefacept 15 mg IM was safe, led to improvement in PPP in all 15 treated patients, and induced a remission in one patient. Larger double-blind studies are warranted.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2310\/7750.2007.00036","type":"journal-article","created":{"date-parts":[[2015,3,11]],"date-time":"2015-03-11T15:01:24Z","timestamp":1426086084000},"page":"202-205","source":"Crossref","is-referenced-by-count":22,"title":["Alefacept is Safe and Efficacious in the Treatment of Palmar Plantar Pustulosis"],"prefix":"10.1177","volume":"11","author":[{"given":"Lyn C.","family":"Guenther","sequence":"first","affiliation":[{"name":"From The Guenther Dermatology Research Centre, London, ON"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2007,11,1]]},"reference":[{"key":"bibr1-7750.2007.00036","doi-asserted-by":"publisher","DOI":"10.2340\/0001555551284288"},{"key":"bibr2-7750.2007.00036","unstructured":"Horgforsen E. Palmoplantar pustulosis. Pathogenetic studies with special reference to the role of nicotine. Acta Univs Ups 2001;1\u201356."},{"key":"bibr3-7750.2007.00036","doi-asserted-by":"crossref","first-page":"289","DOI":"10.2340\/0001555551289294","volume":"51","author":"Enfors W","year":"1971","journal-title":"Acta Derm Venereol"},{"key":"bibr4-7750.2007.00036","doi-asserted-by":"publisher","DOI":"10.2165\/00128071-200203060-00003"},{"key":"bibr5-7750.2007.00036","doi-asserted-by":"publisher","DOI":"10.1111\/1523-1747.ep12495817"},{"key":"bibr6-7750.2007.00036","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.140.5.1401"},{"key":"bibr7-7750.2007.00036","first-page":"624","volume":"2","author":"Gordon KB","year":"2003","journal-title":"J Drugs Dermatol"},{"key":"bibr8-7750.2007.00036","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2001.04411.x"},{"key":"bibr9-7750.2007.00036","unstructured":"Yeung-Yue KA, Aronson PJ, Murakawa GJ. Clinical improvement of palmoplantar pustular psoriasis with alefacept. Poster presentation at the 63rd annual meeting of the American Academy of Dermatology; 2005 Feb 18\u201322; New Orleans, LA."},{"key":"bibr10-7750.2007.00036","first-page":"2745","volume":"52","author":"Fretzin SA","year":"2005","journal-title":"J Am Acad Dermatol"},{"key":"bibr11-7750.2007.00036","unstructured":"Vit\u00e9z L, Wozel G. Severe palmoplantar pustular psoriasis: responsiveness to efalizumab in a treatment-resistant patient. In: Medimond International Proceedings of the 15th EADV Congress Rhodes (Greece), Oct 4\u20138, 2006. p. 779\u201383."},{"key":"bibr12-7750.2007.00036","unstructured":"Dasgeb B, Holzman G, Phillips TJ. An extended 16-week course of alefacept in conjunction with reduced T-cell monitoring for the treatment of chronic plaque psoriasis. Poster presentation at the 63rd annual meeting of the American Academy of Dermatology; 2005 Feb 18\u201322; New Orleans, LA."},{"key":"bibr13-7750.2007.00036","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1747.2003.12094.x"}],"container-title":["Journal of Cutaneous Medicine and Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.2310\/7750.2007.00036","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.2310\/7750.2007.00036","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.2310\/7750.2007.00036","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T15:48:03Z","timestamp":1777391283000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.2310\/7750.2007.00036"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,11]]},"references-count":13,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2007,11]]}},"alternative-id":["10.2310\/7750.2007.00036"],"URL":"https:\/\/doi.org\/10.2310\/7750.2007.00036","relation":{},"ISSN":["1203-4754","1615-7109"],"issn-type":[{"value":"1203-4754","type":"print"},{"value":"1615-7109","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,11]]}}}